Abstract: This disclosure relates to a waste transfer facility. The waste transfer facility includes a first level, the first level positioned at a first height, the first level including a first side, and a second side. The waste transfer facility also includes a second level, the second level positioned at a second height different than the first height, the second level including a plurality of waste receptacles, the plurality of waste receptacles including a first waste receptacle positioned adjacent to the first side to receive waste, a second waste receptacle positioned adjacent to the second side to receive waste, and a non-compliant waste receptacle to receive non-compliant waste, the non-compliant waste to be removed from the waste.

Abstract: This disclosure relates to a waste transfer facility. The waste transfer facility includes a first level, the first level positioned at a first height, the first level including a first side, and a second side. The waste transfer facility also includes a second level, the second level positioned at a second height different than the first height, the second level including a plurality of waste receptacles, the plurality of waste receptacles including a first waste receptacle positioned adjacent to the first side to receive waste, a second waste receptacle positioned adjacent to the second side to receive waste, and a non-compliant waste receptacle to receive non-compliant waste, the non-compliant waste to be removed from the waste.

Abstract: This disclosure relates to a waste transfer facility. The waste transfer facility includes a first level, the first level positioned at a first height, the first level including a first side, and a second side. The waste transfer facility also includes a second level, the second level positioned at a second height different than the first height, the second level including a plurality of waste receptacles, the plurality of waste receptacles including a first waste receptacle positioned adjacent to the first side to receive waste, a second waste receptacle positioned adjacent to the second side to receive waste, and a non-compliant waste receptacle to receive non-compliant waste, the non-compliant waste to be removed from the waste.

Abstract: Embodiments are directed toward a pulley. The pulley preferably has a fixed side plate, an operable side plate, a sheave, and a double-action lock. The operable side plate is preferably transitionable between a closed configuration and an open configuration. The sheave is preferably disposed between the fixed side plate and the operable side plate. The double-action lock is preferably transitionable from a locked configuration to an unlocked configuration upon completion of two separate and distinct actions. The lock in the locked configuration preferably prevents transition of the operable side plate from the closed configuration to the open configuration. The lock in the unlocked configuration preferably permits transition of the operable side plate from the closed configuration to the open configuration.

Abstract: A disposable sleeve. The sleeve includes: a main body fabricated in a generally cylindrical shape from a material suitable for catching fluids associated with a sneeze or cough; a first opening and a second opening, wherein each opening includes an elastic member for holding the disposable sleeve in place on an arm; and a grasping member located proximate each opening for facilitating installation and removal of the disposable sleeve.

Abstract: The present invention provides a recombinant human ?-L-iduronidase and biologically active fragments and muteins thereof with a purity greater than 99%. The present invention further provides large-scale methods to produce and purify commercial grade recombinant human ?-L-iduronidase enzyme thereof.

Abstract: This invention provides compounds of conjugates of therapeutic or active agents with RAP or a RAP polypeptide, their pharmaceutical compositions and methods for using the such compounds and compositions in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly diseases of the central nervous system or lysosomal storage diseases.

Abstract: The present invention provides a highly purified recombinant, human precursor N-acetylgalactosamine-4-sulfatase and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising highly purified recombinant human precursor N-acetylgalactosamine-4-sulfatase. The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant precursor enzyme to a highly purified form.

Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.

Abstract: The present invention provides a recombinant human N-acetylgalactosamine-4-sulfatase (rhASB) and biologically active mutants, fragments and analogs thereof as well as pharmaceutical formulations comprising recombinant human N-acetylgalactosamine-4-sulfatase (rhASB). The invention also provides methods for treating diseases caused all or in part by deficiencies in human N-acetylgalactosamine-4-sulfatase including MPS VI and methods for producing and purifying the recombinant enzyme.

Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.

Abstract: This invention provides compounds of conjugates of therapeutic or active agents with RAP or a RAP polypeptide, their pharmaceutical compositions and methods for using the such compounds and compositions in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly diseases of the central nervous system or lysosomal storage diseases.

Abstract: Schemes for scheduling patients for a time period are described herein. These schemes can compute a financial consequence associated with a medical service provided to a patient. These schemes can determine a schedule of patients for a time period based on one or more criteria selected by a healthcare provider, such as a clinical practice standard and a financial consequence associated with the schedule.